Adlina-EM Tablet 25 mg + 5 mg is a combination oral antidiabetic medication that contains Empagliflozin 25 mg and Linagliptin 5 mg. It is formulated for adults with type 2 diabetes mellitus who require enhanced glycemic control that cannot be achieved with diet, exercise, or single-drug therapy alone. By combining two complementary mechanisms of action, Adlina-EM helps manage blood glucose effectively while providing additional metabolic and cardiovascular benefits.

This tablet is designed to simplify diabetes management by offering the convenience of two active ingredients in a single dose, improving patient adherence and supporting long-term blood sugar control. It should be used in conjunction with a healthy diet, regular exercise, and routine blood glucose monitoring.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Empagliflozin 25 mg

• Linagliptin 5 mg

Mechanism of Action

Adlina-EM combines the actions of an SGLT2 inhibitor and a DPP-4 inhibitor, addressing multiple pathways involved in blood glucose regulation:

Empagliflozin
Empagliflozin inhibits sodium-glucose co-transporter 2 (SGLT2) in the kidneys, preventing glucose reabsorption and increasing urinary glucose excretion. This results in lowered blood glucose levels, modest weight reduction, and potential blood pressure benefits due to osmotic diuresis.

Linagliptin
Linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones (GLP-1 and GIP). By preserving incretin activity, linagliptin stimulates glucose-dependent insulin release and suppresses postprandial glucagon secretion, improving both fasting and post-meal glucose levels.

Together, these mechanisms provide comprehensive glycemic control, targeting both glucose overproduction and insulin insufficiency.

Indications

Adlina-EM Tablet 25 mg + 5 mg is indicated for:

• Management of Type 2 Diabetes Mellitus in adults

• Patients inadequately controlled by diet, exercise, or monotherapy with either empagliflozin or linagliptin

• Combination therapy for enhanced glycemic control

• Patients with cardiovascular risk factors, as empagliflozin has been shown to provide cardiovascular benefits

Benefits

• Dual Mechanism of Action: Controls blood sugar through kidney glucose excretion and enhanced insulin response

• Effective Glycemic Control: Reduces fasting and postprandial glucose levels and lowers HbA1c

• Weight Management Support: Empagliflozin may promote modest weight loss

• Cardiovascular Protection: Demonstrated benefits in patients with established cardiovascular disease

• Low Risk of Hypoglycemia: Especially when used without insulin or sulfonylureas

• Convenient Combination Therapy: Two medicines in one tablet improve adherence and simplify treatment

Dosage and Administration

Adlina-EM Tablet 25 mg + 5 mg is usually taken once daily, preferably in the morning, with or without food. The dosage should be individualized by a healthcare professional based on the patient’s glycemic status, kidney function, and overall treatment goals.

Patients are advised to maintain adequate hydration during therapy. Regular monitoring of blood glucose, HbA1c, and renal function is essential for assessing treatment effectiveness and safety.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Safety and Precautions

• Not suitable for Type 1 diabetes or diabetic ketoacidosis

• Use cautiously in patients with renal impairment

• Increased risk of urinary tract and genital infections due to empagliflozin

• Mild side effects such as headache or gastrointestinal discomfort may occur due to linagliptin

• Rare cases of ketoacidosis have been reported; seek medical attention if symptoms such as nausea, vomiting, abdominal pain, or shortness of breath occur

• Patients should inform their healthcare provider about all medications and medical conditions before starting therapy.